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1. Introduction 
This chapter reviews literature on probiotics. Probiotics are defined and different microbial 
cultures used as probiotics will be considered. It further discusses delivery vehicles for 
probiotic cultures, with their advantages and disadvantages. Since the presence of viable 
probiotic cultures in products is vital to their functionality, different methods used for their 
detection in products will be examined. The beneficial health effects of probiotics, the 
methods that are currently used in an attempt to overcome some of the challenges faced will 
also be discussed. Different strategies for protection of probiotic cultures and challenges for 
the probiotic industry are highlighted. In addition to these, alternative strategies increasing 
numbers of beneficial microorganisms through administration of prebiotics and synbiotics 
are briefly mentioned.  
2. What are probiotics? 
The definition of probiotics has been modified with increasing knowledge in the field of 
how they function. The term is derived from the Greek language meaning ‘for life’. In the 
past there have been many attempts to define the term ‘probiotic’, one of the first being 
described by Lilly & Stillwell in 1965. They defined probiotics as “substances secreted by 
one microorganism, which stimulates the growth of another”. The focus of this definition 
was to distinguish them from and make it clear that they are the opposite of antibiotics. 
Subsequently, in 1974, Parker defined them as “organisms and substances which contribute 
to intestinal microbial balance” (Schrezenmier & de Vrese, 2001). In 1989, Fuller tried to 
improve on Parker’s definition by proposing the following definition: “live microbial feed 
supplement, which beneficially affect the host (animal or human) by improving its intestinal 
microbial balance” (Salminen et al., 1999; Vilsojevic & Shah, 2008). Then, Havenaar & Huis 
In’t Veld (1992) defined probiotics acceptably as ‘a viable mono- or mixed culture of 
microorganisms which applied to animal or man, beneficially affects the host by improving 
the properties of the indigenous microflora’. Schrezenmeir & de Vrese (2001) defined the 
term probiotic as “a preparation of or a product containing viable, defined microorganisms 
in sufficient numbers, which alter the microflora by implantation or colonization, in a 
compartment of the host and by that, exert beneficial effects on host health”. Among these 
descriptions and definitions, there were many others, until the Food and Agriculture 
Organization of the United Nations-World Health Organization (FAO-WHO) officially 
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defined probiotics as: “live microorganisms that when administered in adequate amounts 
confer a significant health benefit on the host” (FAO, 2001). This definition was later endorsed 
by the International Scientific Association for Probiotics and Prebiotics (ISAPP) and is 
currently the most accepted definition of probiotics by scientists worldwide (Reid, 2006).  
Probiotic food cultures have become popular due to appreciation of their contribution to 
good health (Desmond et al., 2002). In probiotic therapy, these beneficial microorganisms 
are ingested and thereby introduced to the intestinal microflora intentionally. This results in 
high numbers of beneficial bacteria to participate in competition for nutrients with and 
starving off harmful bacteria (Mombelli & Gismondo, 2000). The probiotics take part in a 
number of positive health promoting activities in human physiology (Chen & Yao, 2002). 
The beneficial effects of the ingested probiotic bacteria are provided by those organisms that 
adhere to the intestinal epithelium (Salminen et al., 1998). The presence and adherence of 
probiotics to the mucous membrane of the intestines build up a strong natural biological 
barrier for many pathogenic bacteria (Chen & Yao, 2002). Adhesion is therefore regarded as 
the first step to colonization. Adhesion to the epithelium can be specific, involving adhesion 
of bacteria and receptor molecules on the epithelial cells, or non-specific, based on 
physicochemical factors.  
2.1 Desirable properties for a probiotic strain 
A microbial strain has to fulfil a number of specific properties or criteria for it to be regarded 
as a probiotic. These criteria are classified into safety, performance and technological aspects 
(Gibson & Fuller, 2000). The criteria are further dependent on specific purpose of the strain 
and on the location for the expression of the specific property. With regards to safety, the 
probiotic strain must be of human origin, isolated from the gastrointestinal tract (GIT) of 
healthy individuals. They should possess GRAS (generally regarded as safe) status, be non-
pathogenic, and without previous association with diseases such as infective endocarditis or 
gastrointestinal disorders. Probiotic strains must not deconjugate bile salts and they should 
carry no antibiotic resistance genes that can be transferred to pathogens (Collins et al., 1998; 
Saarela et al., 2000). The strain must not induce an immune reaction in the host, i.e. the host 
must be immuno-tolerant to the probiotic (Havenaar & Huis int’Veld, 1992). The strain itself, 
its fermentation products or its cell components after its death, should be non-pathogenic, 
non-toxic, non-allergic, non-mutagenic or non-carcinogenic even in immunocompromised 
individuals (Collins et al., 1998; Havenaar & Huis int’Veld, 1992). It must have 
antimutagenic and anticarcinogenic properties and not promote inflammation in 
individuals (Collins et al., 1998). A probiotic strain should possess a desirable antibiogram 
profile. It must also be genetically stable with no plasmid transfer mechanism (Havenaar & 
Huis int’Veld, 1992; Ziemer & Gibson, 1998). 
With respect to their performance, potential probiotic strains should be acid-tolerant and 
therefore survive human gastric juice and bile. They must be able to survive in sufficient 
numbers and adhere to the intestinal mucosal surface in order to endure the GIT. They 
should have antagonistic activity against pathogens such as Salmonella species, Clostridium 
difficile and Listeria monocytogenes that adhere to mucosal surfaces. Lastly, probiotic strains 
should also stimulate an immune response, thereby positively influencing the host (Biavati 
et al., 2000; Kolida et al., 2006; Mattila-Sandholm et al., 2002; Saarela et al., 2000;). The 
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probiotic should survive the environmental conditions in their target site of action and 
proliferate in this location (Havenaar & Huis int’Veld, 1992). That is, they should be able to 
adhere to and colonise the epithelial cell lining to establish themselves in the colon (Guarner 
& Schaafsma, 1998; Parracho et al., 2007). The ability to adhere to the epithelium secures the 
strain from being easily flushed out by peristaltic movements (Gupta & Garg, 2009). 
Technologically, a good probiotic strain should be easily, inexpensively reproducible 
(Charteris et al., 1998; Havenaar & Huis int’Veld, 1992). It must be able to withstand stress 
during processing and storage, with process and product application robustness (Charteris 
et al., 1998). The organism should be able to survive, in particular, the harsh environmental 
conditions of the stomach and small intestine (e.g. gastric and bile acids, digestive enzymes) 
(Dunne et al., 2001; Parracho et al., 2007).  
In addition, technological aspects must be taken into account before selecting a probiotic 
strain. Strains should be capable of being prepared on a large scale and should be able to 
multiply rapidly, with good viability and stability in the product during storage. The strains 
must not produce off flavours or textures once incorporated into foods. They should be 
metabolically active within the GIT and biologically active against their identified target. 
Probiotic strains must be resistant to phages and have good sensory properties (Collins et 
al., 1998; Kolida et al., 2006; Lacroix & Yildirim, 2007; Mattila-Sandholm et al., 2002; Saarela 
et al., 2000;). Therefore probiotic containing foods and products need to be of good quality 
and must have high enough numbers of viable probiotic cells to ensure that consumers get 
the optimal benefits from the product (Alakomi et al., 2005). Probiotic strains have to be 
good vehicles for specific target delivery of peptides and recombinant proteins within the 
human GIT (Dunne et al., 2001; Parracho et al., 2007). 
2.2 Common probiotic microorganisms 
A number of microorganisms are currently used as probiotics. However, the most 
commonly used are bacteria belonging to the genera Lactobacillus, the first and largest group 
of microorganisms to be regarded as probiotics (Mombelli & Gismondo, 2000; Wolfson, 
1999) and Bifidobacterium. These bacteria are indigenous to the human GIT (Bielecka et al., 
2002; Tannock, 2001). They are known to have no harmful effects, which is in contrast to 
other gut bacteria (Kimoto-Nira et al., 2007). Species of Lactobacilli include L. acidophilus, L. 
rhamnosus , L. casei, L. delbrueckii ssp. bulgaricus, L. johnsonii , L. reuteri, L. brevis, L. cellobiosus, 
L. curvatus, L. fermentum, L. gasseri and L. plantarum (Krasaekoopt et al., 2003; Meurman & 
Stamatova, 2007). The most recognized bifidobacteria species used are Bifidobacterium breve, 
B. animalis subsp lactis formerly B. lactis (Masco et al., 2004) and B. longum biotypes infantis 
and longum (Masco et al., 2005).  
Probiotics now include other lactic acid bacteria (LAB) from genera such as Streptococcus, 
Lactococcus, Enterococcus, Leuconostoc, Propionibacterium, and Pediococcus (Krasaekoopt et al., 
2003; O’Sullivan et al., 1992; Power et al., 2008; Vandenplas et al., 2007; Vinderola & 
Reinheimer, 2003). Some countries are, however, concerned about the possible transfer of 
antibiotic resistance genes by some members of the Enterococcus (Lund & Edlund, 2001). 
Other non-related microbes used include bacteria such as non-pathogenic E. coli Nissle 1917 
and Clostridium butyricum (Harish & Varghese, 2006), yeasts (Saccharomyces cereviciae, 
Saccharomyces boulardii), filamentous fungi (Aspergillus oryzae), and some spore forming 
bacilli (Fuller, 2003; Mombelli & Gismondo, 2000; Wolfson, 1999). 
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2.3 Probiotic products 
Probiotics can be consumed either as food components or as non-food preparations (Stanton 
et al., 1998). Foods containing probiotics are referred to by others as functional foods. This 
refers to foods with nutrient or non-nutrient components that affect targeted function(s) in 
the body resulting in a positive health effect (Bellisle et al., 1998). Thus, functional foods 
have a physiological or psychological effect beyond basic nutritional value (Clydesdale, 
1997). Several probiotic LAB strains are available to consumers in both traditional fermented 
foods and in supplemented form (Kourkoutas et al., 2005). The majority of probiotics are 
incorporated into dairy products such as milk powders, yoghurt, soft-, semi-hard and hard 
cheeses and ice cream (Desmond et al., 2005; Dinakar & Mistry, 1994; Stanton et al., 2001; 
Stanton et al., 2005). These products offer a suitable environment for probiotic viability and 
growth (Özer et al., 2009; Ross et al., 2002). There is an increase in use of other foods as 
vehicles for probiotics. This is partly due to allergenicity of some consumers to milk 
products. Non-dairy products such as malt-based beverages and fruit juices (Champagne & 
Raymond, 2008; Rozada-Sanchez et al., 2007; Sheehan et al., 2007), meat sausages (Ruiz-
Moyano et al., 2008), capsules, and freeze-dried preparations (Berni-Carnani et al., 2007) are 
among these alternatives. Growing vegetarian alternatives have also led to soy-based 
probiotic foods (Farmworth et al., 2007). Recently, Aragon-Alegro et al. (2007) added 
probiotic chocolate mousse to the list of alternatives.  
2.4 Beneficial effects of probiotics 
The benefits attributed to probiotics can either be nutritional or therapeutic (Prasad et al., 
1998). Benefits associated are, however, strain specific (Saarela et al., 2000). 
2.4.1 Nutritional benefits 
Microbial action in the gut, specifically by beneficial cultures, has been shown to enhance 
the bioavailability, quantity and digestibility of certain nutrients (Parvez et al., 2006). 
Ingestion of probiotics is associated with improved production of riboflavin, niacin, 
thiamine, vitamin B6, vitamin B12 and folic acid (Gorbach, 1997; Hargrove & Alford, 1978). 
Probiotics play a role in increasing bioavailability of calcium, iron, manganese, copper, 
phosphorous (Alm, 1982; McDonough et al., 1983) and increase the digestibility of protein 
and fat in yoghurt (Fernandes et al., 1987). Enzymatic hydrolysis of protein and fat leads to 
an increase in free amino acids and short chain fatty acids (SCFAs). Organic acids such as 
acetate and lactate produced during fermentation by LAB lower the pH of intestinal 
contents thereby creating undesirable conditions for harmful bacteria (Mack et al., 1999; 
Parvez et al., 2006). 
2.4.2 Therapeutic benefits 
Patients prefer medicine with little or no side effects for treatment of their ailments. 
Probiotics provide such an alternative, being living, non-pathogenic organisms, which are 
extremely safe as indicated by their GRAS status. Probiotic bacteria are claimed to alleviate 
and prevent conditions such as lactose intolerance, allergies, diarrheal diseases, lowering of 
serum cholesterol, reduction of the risk associated with mutagenicity and carcinogenicity 
and inhibition of pathogens, as well as stimulation of the immune system (Collins & Gibson, 
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1999; Shah, 2007). Positive effects of probiotics are not confined to the gut only, but can 
extend to other parts of the body. For instance, probiotics are known to have anti-
inflammatory benefit when administered parenterally (Shiel et al., 2004).  
Lactose malabsorption (also referred to as lactose intolerance or lactose indigestion) is the 
inability to hydrolyze lactose (Adams & Moss, 2000; Salminen et al., 1998a). It is caused by a 
deficiency of the enzyme β-D-galactosidase (lactase) (Buller & Grand, 1990). The undigested 
lactose passes to the colon where it is attacked by resident lactose fermenters (Adams & 
Moss, 2000). Colonic lactose fermentation results in high levels of glucose in blood and 
hydrogen gas in breath (Buller & Grand, 1990; Mombelli & Gismondo, 2000; Scrimshaw & 
Murray, 1988; Shah, 1993; Vesa et al., 2000). Probiotics strains and the traditional yoghurt 
cultures, Lactobacillus delbrueckii spp. bulgaricus and Streptococcus thermophilus produce β-D-
galactosidase thereby improving tolerance to lactose (Adams & Moss, 2000; Fooks et al., 
1999, Shah, 2000c) 
Constipation, a disorder of motor activity of the large bowel characterized by bowel 
movements that are less frequent than normal (Salminen et al., 1998b), pain during 
defecation, abnormal swelling and incomplete emptying of colon contents (Salminen et al., 
1998a), can also be relieved by probiotic use. Lactobacillus reuteri, Lactobacillus rhamnosus and 
Propionibacterium freudenreichii are probiotic strains shown to improve the condition 
(Ouwenhand et al., 2002). 
Incidences of antibiotic associated diarrhoea caused by Clostridium difficile (Fuller, 2003; 
Tuohy et al., 2003; Vasiljevic & Shah, 2008) and rotavirus diarrhoea (Salminen et al., 
1998a) can also reduced by administration of probiotics. Strains associated with reduction 
of diarrhoea include Bifidobacterium spp, B. animalis Bb12 (Fuller, 2003, Guandalini et al., 
2000), L. rhamnosus GG, L. acidophilus, L. bulgaricus (Fuller, 2003; Goldin, 1998; Gorbach, 
2000; Sazawal et al., 2006) and Saccharomyces boulardii (Kotowska et al., 2005, Sazawal et 
al., 2006). The effect of probiotics against diarrhoea is the most researched and 
substantiated claim, with documented clinical applications (BergogneBérézin, 2000; 
Cremonini et al., 2002; Marteau et al., 2001, McNaught & MacFie, 2001; Reid et al., 2003; 
Sullivan & Nord 2005).  
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are other intestinal 
disorders that can be treated with varying degrees of success using probiotics. IBD is a 
collection of disorders including ulcerative colitis, Crohn’s disease and pouchitis, 
characterized by chronic or recurrent inflammation, ulceration and abnormal narrowing of 
the GIT resulting in abdominal pain, diarrhoea and gastrointestinal bleeding (Hanauer, 
2006; Marteau et al., 2001). IBS is typically characterized by abdominal pain, excessive flatus, 
variable bowel habit and bloating (Madden & Hunter, 2002). Several studies have been 
conducted to investigate the efficacy of probiotics in treatment of IBD (Guandalini, 2002; Ma 
et al., 2004; Zhang et al., 2005). The tested strains against IBD include among others VSL#3 
probiotic (Gionchetti et al., 2000), Bifidobacterium longum (Furrie et al., 2005) and Lactobacillus 
rhamnosus GG (Gupta et al., 2000). Combination of Lactobacillus acidophilus and 
Bifidobacterium infantis (Hoyos, 1999) and of Bifidobacterium bifidus, Bifidobacterium infantis 
and Streptococcus thermophilus were shown to reduce incidences of ulcerative colitis (Bin-
Nun et al., 2005). Several studies reported the success of bifidobacteria for the alleviation of 
IBS (O’Mahony et al., 2005; Brenner et al., 2009; Jankovic et al., 2010). Alfredo (2004) 
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demonstrated the efficacy of Lactobacillus plantarum LP01 and Bifidobaccterium breve BR0 as 
short-term therapy for IBS. Although some of the results obtained were very encouraging, 
there is need for larger, randomized, double-blinded, placebo-controlled clinical trials to 
substantiate these claims.  
Hereditary allergic conditions of increasing importance in developing countries such as 
eczema, asthma, atopic dermatitis and rhinitis can be treated with probiotics (Holgate, 1999; 
Kalliomaki et al., 2003; Salminen et al., 1998a). Tested probiotics with antiallergenic 
properties include Bifidobacterium lactis Bb-12 (Isolauri et al., 2000) and Lactobacillus GG 
(Isolauri et al., 2000; Kalliomaki et al., 2001; Kalliomaki et al., 2003; Lee et al., 2008; Mirkin, 
2002; Vanderhoof & Young, 2003). However, contradictory studies report on the poor 
efficiency of probiotics in allergy alleviation (Helin et al., 2002; Vliagoftis et al., 2008) and 
highlight the need for more convincing and conclusive research in allergy treatment.  
Probiotics have the ability to lower levels of cholesterol in serum, contributing to the 
prevention of cardiovascular disease (Fooks et al., 1999; Proviva, 2002). This ability has been 
shown for Lactobacillus johnsonii and L. reuterii using animal models (Mombelli & Gismondo, 
2000). They also reduce the risk of cancer (Sanders, 1999) due to their activity against certain 
tumors (Chen & Yao, 2002). Several studies indicated that probiotics in a diet reduces the 
risk of cancer (Sanders, 1999). Anticarcinogenic effects of Bifidobacterium bifidum and 
Lactobacillus acidophilus were shown using clinical trials in humans (Fooks, 1999).  
2.5 Mechanism of action of probiotics 
Probiotic bacteria beneficially affect the individual by improving the properties of the 
indigenous microflora and its microintestinal balance (Betoret et al., 2003; Frost & Sullivan, 
2000; Matilla-Sandholm et al., 2002; Saarela et al., 2000). They compete with disease causing 
bacteria for villi attachment sites and nutrients (Chen & Yao, 2002). Probiotic bacterial 
cultures encourage growth of beneficial microorganisms and crowd out potentially harmful 
bacteria thereby reinforcing the body’s natural defence mechanisms (Saarela et al., 2000). 
They provide specific health benefits by modifying gut microflora, strengthening gut 
mucosal barrier, e.g. adherence of probiotics to the intestinal mucosa thereby preventing 
pathogen adherence, pathogen inactivation, modification of dietary proteins by intestinal 
microflora, modification of bacterial enzyme activity, and influence on gut mucosal 
permeability, and regulation of the immune system (Betoret et al., 2003; Krasaekoopt et al., 
2003; Salminen et al., 1998). 
The probiotic effect is accredited to their production of metabolic by-products such as acid, 
hydrogen peroxide, bacteriocins, e.g. lactocidin, and acidophilin that manifest antibiotic 
properties and inhibit the growth of a wide spectrum of pathogens and/or potential 
pathogens such as Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, Salmonella, Serratia and 
Bacteroides (Chen & Yao, 2002; Krasaekoopt et al., 2003). Lactic acid bacteria inhibit growth of 
pathogenic microorganisms by producing short chain fatty acids such as acetic, propionic, 
butyric as well as lactic and formic acids which reduces intestinal pH. Lactic acid produced by 
bifidobacteria in substantial amounts has antimicrobial activity against yeasts, moulds and 
bacteria (Adams & Moss, 2000; Percival, 1997). These species are also active in reducing the 
faecal activity of enzymes implicated in the production of genotoxic metabolites such as β-
glucoronidase and glycolic acid hydroxylase (Collins & Hall, 1984; Mombelli & Gismondo, 
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2000). Probiotic organisms produce enzymes that help in digestion of proteins, fats and lactose 
(Frost & Sullivan, 2000). They also produce β-galactosidase, an enzyme that aid lactose 
intolerant individuals with breaking down or digestion of lactose (Krasaekoopt et al., 2003). 
Production of short chain fatty acids in the colon during fermentation by colonic microflora 
is the main process that prevents colorectal cancer (Holzapfel & Schillinger, 2002). Probiotic 
strains also reduce levels of some colonic enzymes such as glucoronidase, β-glucoronidase 
nitroreductase, azoreductase (Adams & Moss, 2000; Chen & Yao, 2002; Fooks et al., 1999; 
Gorbach, 2000) and glycoholic acid hydrolase. These enzymes convert procarcinogens to 
carcinogens such as nitrosamine or secondary bile acids (Chen & Yao, 2002). Low levels of 
these enzymes therefore decrease chances of cancer development in the colon (Gorbach, 
2000; Kasper, 1998). 
2.6 Methods for quantification of probiotic cultures 
The methods used for detection of viable probiotic cells include conventional plate counts 
(culture dependent) and molecular techniques (culture-independent). The culture 
dependent method has been criticized for underestimation of counts due to bacteria forming 
chains and/or clumping and unsuitability (inappropriateness) of media for growing of 
viable but non-culturable cells (Auty et al., 2001; Lahtinen et al., 2006; Veal et al., 2000). 
Isolation media used may be insufficiently selective, affecting the reproducibility of results 
(Roy, 2001). These limitations of plate counting techniques prompted the use of molecular 
techniques and other alternative methods (Vitali et al., 2003). New methods include 
molecular based techniques such as quantitative real-time polymerase chain reaction (PCR), 
fluorescent in situ hybridization (FISH) (Boulos et al., 1999; Veal et al., 2000), confocal 
scanning laser microscopy (CSLM) (Auty et al., 2001; Gardiner et al., 2000; Palencia et al., 
2008), flow cytometry (Alakomi et al., 2005) and microplate scale fluorochrome staining 
assay (Filoche et al., 2007; Mättö et al., 2006).  
Flow cytometry is a rapid and sensitive technique that measures physiological 
characteristics such as membrane integrity, enzyme activity, respiration, membrane 
potential and intracellular pH (Bunthof et al., 2001) of each cell individually (Bunthoff & 
Abee, 2002). Microplate scale fluorochrome staining assay is appropriate for assessing 
viability of fresh, freeze-dried and stressed cells. It can detect changes in the condition of 
probiotic cells earlier than can be done with conventional cultivation methods (Filoche et al., 
2007; Mättö et al., 2006).  
The fluorescence based molecular techniques are used in conjunction with viability staining 
techniques. A number of commercial techniques are available. LIVE/DEAD® BacLight™ 
and BD Cell viability assay kit (BD Biosciences, Oxford, UK) are some examples. 
LIVE/DEAD® BacLight consists of two nucleic acid stains SYTO® 9 and propidium iodide 
(PI). Green-fluorescent SYTO9 (excitation and emission maxima, 480 and 500 nm, 
respectively) penetrates both viable and nonviable cells. Red-fluorescent PI (excitation and 
emission maxima, 490 and 635 nm, respectively) penetrates cells with damaged cell 
membranes (Auty et al., 2001). The BD Cell viability assay kit (BD Biosciences, Oxford, UK) 
contains the stains, thiazole orange and propidium iodide (Doherty et al., 2009). Cells 
stained using these kits can also be assessed using microscopes, which will also distinguish 
between ‘live’ (e.g. green-stained) from ‘dead’ (e.g. red-stained) cells (Berney et al., 2007).  
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All the above mentioned methods have their own disadvantages. For example, the viability 
kits and real time PCR are based on bacterial DNA which is not only present in live cells but 
can also be retained by dead cells in significant amounts. Both PCR and FISH are not 
independent as they require determination of a standard curve which is determined most of 
the times using standard plate counts. PCR requires expensive reagents which cannot be 
afforded by everyone in the industry. Detection limits for PCR and FISH are relatively high, 
being about 104 cells/ml and 106 cells/ ml, respectively. FISH is based on detection of 16s 
rRNA whose presence is not a direct proof of metabolic activity but rather an indication of 
potential viability (Biggerstaff, 2006). Real-time PCR and FISH have a limitation whereby 
counts of bacteria decreased but PCR and FISH results remained higher over the 
experimental period. This is due to detection of high levels of rRNA and DNA in dead cells. 
The intensity of rRNA in dead cells may still be strong enough for visually counting 
(detection) though it is expected to decrease upon cell death. Thus, the RNA content of the 
cell detected by fluorescent probes cannot be regarded as reliable indicator of cellular 
viability (Vives-Rego et al., 2000). Also, real time PCR detects both viable and non-viable 
bacteria, thus does not provide information on the condition of the cells and results in an 
overestimation of metabolically active cells (Kramer et al., 2009; Masco et al., 2007).  
The appropriateness of PCR for quantification of viable cells can be improved by staining 
the samples with DNA binding dyes prior to DNA extraction and amplification. Treatment 
with DNA-binding dyes and subsequent PCR analysis uses membrane integrity as the 
criterion in determining viability of cells. Live cells are able to exclude DNA-binding dyes 
such as ethidium monoazide (EMA) and propidium monoazide (PMA), while dead cells or 
those whose membrane integrity has been compromised are able to pick-up these stains 
(Kramer et al., 2009). These dyes form covalent bonds with DNA upon exposure to visible 
bright light and thus inhibit subsequent PCR amplification. Only DNA from live cells with 
intact membranes is selectively amplified (Nocker et al., 2009).  
Despite some of its drawbacks, the plate count method is traditionally used to assess cell 
viability in probiotic preparations (Alakomi et al., 2005). Though plate counting is arduous 
and time consuming, no method has yet been found that completely replaces it. Therefore it 
is still being routinely used in assessing viability of probiotic cultures in various foods, often 
in conjunction with culture-independent methods (Lopez-Rubio et al., 2009; Masco et al., 
2005; Temmerman et al., 2003b).  
2.7 Probiotic challenges 
Commercially, viable probiotic strains are incorporated into fermented food products or are 
supplied as freeze-dried supplements or pharmaceutical preparations (Holzapfel & 
Schillinger, 2002). The basic requirement for probiotics is that products should contain 
sufficient numbers of microorganisms up to the expiry date (Fasoli et al., 2003). Thus, 
probiotics must contain specific strains and maintain certain numbers of live cells for them 
to produce health benefits in the host (Mattila-Sandholm et al., 2002). Different countries 
have decided on the minimum number of viable cells required in the probiotic product for it 
to be beneficial. In Australia, a minimum viable count of 106 organisms per gram should be 
available in fermented milk products at the end of the shelf life (Wahlqvist, 2002). However, 
according to Krasaekoopt et al. (2003), there are no specifications as to how many probiotics 
should be available in Australian fermented products. The same minimum count (106 
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organisms per gram) was approved by countries of MERCOSUR which includes Argentina, 
Paraguay, Brazil and Uruguay (Krasaekoopt et al., 2003). In products containing multiple 
probiotic organisms, at least a million of each of them per gram should be present to 
produce required beneficial effects (Wahlqvist, 2002). In Japan, a minimum of 107 viable cells 
per millilitre of fresh dairy product is required. The South African legislation states that 
functional foods containing probiotic bacteria must deliver 1 x 108 bacterial cells per day. A 
daily intake of 109 to 1010 cfu viable cells is considered the minimum dose shown to have 
positive effects on host health (Fasoli et al., 2003). This could be achieved by consuming 100 
g of a product containing between 106 and 107 viable cells g-1 daily (Boylston et al., 2004). 
Low viability of probiotic cultures in yoghurt has been reported (Kailasapathy & Rybka, 
1997; Lourens-Hattingh & Viljoen, 2001; Shah, 2000).  
Retention of viability of the probiotic bacteria presents a major marketing and technological 
challenge for application of probiotic cultures in functional foods (Desmond et al., 2002; 
Mattila-Sandholm et al., 2002). Many active cultures die during manufacturing, storage or 
transport of the finished product (Siuta-Cruce & Goulet, 2001) and also during the passage 
to the intestine (Sakai et al., 1987; Siuta-Cruce & Goulet, 2001; Park et al., 2002). Thus, the 
majority die even before the consumer receives any of the health benefits (Siuta-Cruce & 
Goulet, 2001). A serious problem of shelf instability had been encountered with dried 
cultures. Refrigerated products also have short lives due to negative effects of low 
temperature and formation of crystals on bacterial cells. The numbers of viable bacteria 
continually decrease with time during refrigerated storage (Porubcan et al., 1975). Market 
surveys have revealed much lower counts in the products even before the expiry date 
(Talwalkar et al., 2001). Shelf life for probiotics is thus unpredictable; hence, the industry has 
had difficulty backing up label claims (Siuta-Cruce & Goulet, 2001). Excesses of 50 to 200 % 
cells have been incorporated into products in an attempt to make-up for cells that die during 
storage. For example, in tablets containing dry cells, where the tablets are labelled as 
containing a certain minimum count of active cells per tablet, to be safe, the manufacturer 
must incorporate an excess of cells at the time the tablets are manufactured, thereby 
assuring that the labelling will remain accurate while the product is in stock by the retailers. 
This practice increases the cost and makes the use instructions inaccurate (Porubcan et al., 
1975). 
Probiotics, after surviving food processing, are upon consumption then exposed to 
conditions prevailing in the stomach and small intestine before they reach their site which is 
the colon (Siuta-Cruce & Goulet, 2001; Hansen et al., 2002; Lian et al., 2002). The microbes 
may die during their transit through the upper intestinal tract to the colon and therefore 
they may not be able to colonize the colon (Talwakar et al., 2001). They must therefore 
survive gastric acidity and bile salts which they encounter during their passage through the 
GIT (Hansen et al., 2002; Lian et al., 2002; Sakai et al., 1987; Siuta-Cruce & Goulet, 2001;). 
Their survival in the GI T depends on the strain and species-specific resistance to low pH 
(pH values ranging from 1.3 to 3.0) in gastric juice and to bile salts found in the small 
intestine (Hansen et al., 2002; Lian et al., 2002). 
Probiotic bacteria can only perform when they find adequate environmental conditions and 
when they are protected against stresses (e.g extreme temperatures, high pressure, shear 
forces) they encounter during their production at the industry level or in the GIT (gastric 
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acids and bile salts) (Siuta-Cruce & Goulet, 2001). Factors affecting viability during storage 
such as temperature, moisture, light and air should also be taken into consideration 
(Percival, 1997; Mattila-Sandholm et al., 2002). Oxygen toxicity is another major problem in 
the survival of probiotic bacteria in dairy foods. High levels of oxygen in the product are 
detrimental to the viability of these anaerobic bacteria (Talwakar et al., 2001). 
Manufacturers of probiotics are facing the challenge that they should produce probiotic 
cultures that can survive for long periods, and are resistant to acidity in the upper intestinal 
tract so that they can reach the colon in high numbers to colonize the epithelium. Probiotic 
cultures should therefore be produced in a way that will protect these sensitive bacteria 
from unfavourable interactions with detrimental factors (Siuta-Cruce & Goulet, 2001). 
In view of the health benefits associated with probiotics, it is not surprising that there is 
increasing interest in their viability. Probiotics do not have a long shelf life in their active 
form. Refrigeration is required in most cases to maintain shelf life as high temperatures can 
destroy probiotic cultures (Saxelin et al., 1999). However, most probiotics still have a short 
shelf-life even under low temperature storage (Lee & Salminen, 1995). There is low recovery 
of viable bacteria in products claiming to contain probiotic bacteria (Hamilton-Miller et al., 
1999; Temmerman et al., 2003a).  
The preservation of these probiotic microorganisms presents a challenge because they are 
affected by exposure to temperature, oxygen and light (Bell, 2001; Chen et al., 2006). 
Survival of most bifidobacteria in most dairy products is poor due to low pH and/or 
exposure to oxygen (Gomes & Malcata, 1999). Naturally many LAB may excrete exo-
polysaccharides to protect themselves from harsh conditions but this is usually not enough 
to give them full protection (Shah, 2002). 
2.8 Methods for improving probiotic viability 
In view of the health benefits associated with probiotics, it is not surprising that there is an 
increasing interest in their viability. The common practice is storage at refrigerated 
temperatures to prolong their shelf life (Saxelin et al., 1999). Nevertheless, most of them still 
have a short shelf-life (Lee & Salminen, 1995). There is low recovery of viable bacteria in 
products claiming to contain probiotic bacteria (Hamilton-Miller et al., 1999; Temmerman et 
al., 2003a).  
Viability of probiotics is reduced as a result of their exposure to high temperature, oxygen, 
low pH and light (Bell, 2001; Chen et al., 2006; Gomes & Malcata, 1999). Naturally many 
LAB may excrete exo-polysaccharides (EPS) to protect themselves from harsh conditions. 
However, protection afforded by these EPS is not sufficient (Shah, 2002). As a result, 
researchers are continuously searching for ways to improve survival of probiotic cultures 
during processing, storage and GIT transit. Different approaches are used in an attempt to 
preserve viability of probiotic cultures. These include among others, pre-exposure of 
probiotic cultures to sub-lethal stresses (Desmond et al., 2002) and incorporation of micro-
nutrients such as peptides and amino acids (Shah, 2000). The disadvantage of pre-exposure 
to sublethal stresses is that it may result in significant decreases in cellular activity, cell yield 
and process volumetric productivity (Doleyres & Lacroix, 2005). Other alternative methods 
for improving probiotic viability are genetic modification (Sheehan et al., 2006; Sheehan et 
al., 2007; Sleator & Hill, 2007), immobilization (Doleyres et al., 2004), two-step fermentations, 
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use of oxygen-impermeable containers and microencapsulation (Özer et al., 2009). Of these 
techniques, microencapsulation is relatively new and has been investigated by various 
researchers.  
Microencapsulation is a process by which solids, liquids or gases are packaged into 
miniature, sealed microcapsules that can release their contents at controlled rates under 
influences of specified conditions (Anal et al., 2006; Anal & Singh, 2007). It stabilizes the 
probiotics, increases their survival during processing and storage, controls the oxidative 
reaction, ensures sustained or controlled release at a specific target site (both temporal and 
time-controlled release) and improves shelf life (Anal & Singh, 2007; Dembczynski & 
Jankowski, 2002). The encapsulated probiotics are released from the microparticles as a 
result of many factors such as changes in pH and/or temperature (Gibbs et al., 1999; 
Vasishtha, 2003). These changes may cause microcapsule walls to swell and rupture or 
dissolve (Franjione & Vasishtha, 1995; Brannon-Peppas, 1997).  
Microparticles reduce loss of probiotic cell viability by blocking reactive components such as 
atmospheric moisture, oxygen (Kim et al., 1988; Krasaekoopt et al., 2003; Reid, 2002; Siuta-
Cruise & Goulet, 2001; Vasishtha, 2003), high temperature, pressure, bacteriophage attack 
and cryoeffects (Krasaekoopt et al., 2003). Studies have indicated that probiotic cultures 
enclosed within solid fat microcapsules retain both their activity and vitality (Krasaekoopt et 
al., 2003).  
Methods of microencapsulation used in pharmaceutical and food industries are classified 
as either physical or chemical. Physical methods include pan coating, air-suspension 
coating, centrifugal extrusion, vibrational nozzle and spray drying (Anal & Singh, 2007), 
spray coating, annular jet, spinning disk, spray cooling, spray drying and spray chilling 
(Versic, 1988), extrusion coating, fluidized bed coating, liposome entrapment, 
coarcervation, inclusion complexation, centrifugal extrusion and rotational suspension 
separation (Vasishtha, 2003). Chemical methods include interfacial polymerization, in-situ 
polymerization, matrix polymerization(Vidhyalakshmi et al., 2009) and extrusion. 
Extrusion and emulsion techniques are the mostly commonly used methods (Krasaekoopt 
et al., 2003).  
There is a diversity of materials used for encapsulation of probiotics. These include among 
others, alginate (Chandramouli et al., 2004; Dembczynski & Jankowski, 2002; Hansen et al., 
2002; Krasaekoopt et al., 2003; Sultana et al., 2000), к-carrageenan, locust bean gum, cellulose 
acetate phthalate, chitosan, gelatin (Krasaekoopt et al., 2003), cellulose (Chan & Zhang, 
2002), pectin, whey protein (Guerin et al., 2003) and rennet (Heidibach et al., 2009). These 
materials are used either as supporting materials or gelling agents by different investigators.  
Although generally there are positive effects of microencapsulation, this method is not 
without disadvantages. Some types of the resulting microparticles may shrink and lose 
mechanical strength due to their sensitivity to acids (Sun & Griffiths, 2000), may present 
problems for large scale production, others require use of potassium ions that should not be 
taken in large amounts in diet, (Sun & Griffiths, 2000), some of the polysaccharides used are 
prohibited in specific foods in other countries (Picot & Lacroix, 2004). Additionally and 
possibly the key disadvantage, is that the mentioned microencapsulation methods use water 
and other organic solvents whose use is less favoured due to their high costs and concerns 
about their negative environmental impacts (Sihvonen et al., 1999).  
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Progress towards elimination of use of organic solvents has been made with development of 
microencapsulation technique using supercritical technology (Moolman et al., 2006). This 
microencapsulation technique is based on the formation of an interpolymer complex 
between poly (vinyl pyrrolidone) (PVP) and poly (vinyl acetate-co-crotonic acid) (pVA-CA) 
in supercritical carbon dioxide (scCO2). A supercritical substance is neither a gas nor a liquid 
but possesses properties of both, making it unique (Moshashaee et al., 2000). Since 
supercritical fluids have a wide spectrum of solvent characteristics, they can be used as 
solvents in different techniques (Frederiksen et al., 1997). Microparticles produced using this 
method have suitable morphological characteristics, encapsulation efficiency and affords 
encapsulated probiotic cultures protection in simulated gastrointestinal fluids (Mamvura et 
al., 2011; Thantsha et al., 2009).  
2.9 Concerns about probiotics 
Although there are numerous advantages and health benefits associated with probiotics or 
probiotic food products, there are risks associated with probiotic therapy. These risks are 
mainly concerned with respect to safety in vulnerable target groups such as 
immunocompromised individuals (pregnant women, babies and the elderly) or critically ill 
or hospitalized patients (Boyle et al., 2006; Jankovic et al., 2010). 
Probiotic cultures are resistant to some antibiotics. There is concern about the possible 
transfer of antimicrobial resistance from probiotic strains to pathogenic bacteria in the gut. 
For example, many Lactobacillus strains are naturally resistant to vancomycin, which poses a 
potential threat of transfer of this resistance to other pathogenic bacteria such as 
Staphylococcus aureus. However, these vancomycin-resistant genes in lactobacilli are 
chromozomal and not readily transferred to other species. 
Another important area of concern is the risk of sepsis. There have been several reports of 
cases of Lactobacillus sepsis and other bacterial sepsis due to the intake of probiotic 
supplements (Boyle et al., 2006). One case included a 67 year-old man who was taking 
probiotic capsules daily for mitral regurgitation and developed Lactobacillus rhamnosus 
endocarditis after a dental procedure (Borriello et al., 2003; Mackay et al., 1999). In another 
case, a 4-month old infant with antibiotic-associated diarrhoea, who was given Lactobacillus 
rhamnosus after cardiac surgery, developed Lactobacillus endocarditis 3 weeks after 
Lactobacillus rhamnosus treatment (Boyle et al., 2006; Kunz et al., 2004). However, there have 
been no reports to date on the occurrence of Bifidobacterium sepsis. All cases of bacterial 
sepsis from the use of probiotics (Lactobacillus spp.) have occurred in immunocompromised 
individuals or patients who have a chronic disease or debilitation. No cases have been 
reported in healthy individuals (Boyle et al., 2006). There have also been several cases of 
fungemia associated with Saccharomyces boulardii. However, investigation of these cases 
revealed that the infection was due to contamination of inserted catheters. It is therefore 
now recommended that Saccharomyces boulardii probiotics be prepared in powdered form 
under stringent hygienic conditions to prevent contamination (Borriello et al., 2003; 
Salminen et al., 1998). There is a small risk of adverse metabolic effects from manipulation of 
the microbiota with the use of probiotics, although probiotic studies to date have not shown 
significant adverse effects on growth or nutrition (Boyle et al., 2006). A review of safety 
assessments of probiotics was recently published (Sanders et al., 2010). 
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3. Prebiotics 
Prebiotics are non-digestible food ingredients that beneficially affect the host by selectively 
stimulating the growth and/or activity of one or a limited number of colonic bacteria and 
thereby improve host health (Femia et al., 2002; Gibson & Roberfroid, 1995; Roberfroid, 
1998; Theuer et al., 1998; Tuohy et al., 2003; Young, 1998). Gibson et al. (2004) redefined 
them as ‘a selectively fermented ingredient that allows specific changes; both in the 
composition and/or activity in the gastrointestinal microflora that confers benefits to host 
well-being and health’. The refined definition takes into account both the microbial changes 
and the nutritional and physiological benefits attributed to prebiotics. Just like probiotics, 
they modulate the composition of the natural ecosystem though probiotics does so through 
introduction of exogenous bacteria into the colon (Bouhnik et al., 2004). Prebiotics pass 
through the upper GIT unfermented and are only utilized in the colon and are therefore 
called ‘colonic food’ (Roberfroid, 2000). Non-digestibility can be demonstrated in vitro by 
subjecting the carbohydrates to pancreatic and small intestinal enzymes. It can be shown in 
vivo on human subjects with an ileostomy (i.e people who have had their large intestine 
removed and have a stoma at the end of the ileum) (van Loo et al., 1999). Compounds that 
are not digested and absorbed by the host but are preferentially fermented by Bifidobacterium 
species in the colon are called ‘bifidogenic’ factors (Shah, 2007). Prebiotics are not readily 
digested by pathogenic bacteria (Annika et al., 2002; Farmer, 2002; Femia et al., 2002). They 
favour or promote growth of potentially health-promoting bacteria such as lactobacilli and 
bifidobacteria, thereby allowing them to be predominant (Bouhnik et al., 2004; Flamm et al., 
2001; Gibson et al., 1999; Roberfroid, 1998; Wang, 2009). This subsequently leads to 
predominant numbers of the stimulated endogenous bacteria in faeces as well (Femia et al., 
2002; Losada & Olleros, 2002). Scientific studies in Japan indicated that consumption of 
prebiotics increases the populations of bifidobacteria and other beneficial microorganisms 
even in the absence of probiotics in diet. The selective stimulation of growth of 
bifidobacteria by prebiotics is characterized by a substantial decrease in numbers of 
potentially pathogenic bacteria (Losada & Olleros, 2002).  
The following criteria are used for selection of a carbohydrate as a prebiotic: It must not be 
absorbed in the stomach or small intestine; It must be selectively fermented by the beneficial 
gut microflora; It should also stimulate the growth and/or activity of beneficial bacteria; Its 
fermentation should induce the beneficial luminal or systemic effects within the host; It 
must be resistant to gastric acidity and mammalian enzyme hydrolysis (Kolida, et al., 2002; 
Manning and Gibson, 2004). 
Classes of non-digestible oligosaccharides (NDOs) commercially available are cyclodextrins, 
fructooligosaccharides (FOS), gentiooligosaccharides, glycosylsucrose and isomaltulose (also 
known as palatinose). Other classes include lactulose, lactosucrose and maltooligosaccharides 
(Sako et al., 1999). NDOs such as inulin, fructooligosaccharide, lactulose and dietary fibre are 
common prebiotics (Davis & Milner, 2009). There are conflicting views on the prebiotic 
classification of resistant starch. Some researchers classify it as a prebiotic (Douglas & Sanders, 
2008) while others (Shah, 2004) differ, arguing that resistant starch is not digested by some 
beneficial bacteria, and therefore cannot be classified as a prebiotic. Inulin and FOS are the 
only NDOs that have been sufficiently studied to give adequate data to analyze their 
functional properties (Roberfroid, 2000). Galacto-oligosaccharides (GOS), gluco-
oligosaccharides, lactulose, isomalto-oligosaccharides, raffinose, transgalacto-oligosaccharides, 
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xylo-oligosaccharides, soya bean oligosaccharides and oat β-glucans are considered as 
prebiotic candidates (Lomax & Calder, 2009). Other NGOs such as lactulose (Crittenden & 
Playne, 1996) and xylobiose (Vazquez et al., 2000) are also included in the prebiotic category. 
All the prebiotic candidates except maltooligosaccharides, glycosylsucrose and cyclodextrins 
are reported as being bifidogenic (Ziemer & Gibson, 1998).  
Prebiotics are found naturally in a number of materials. Honey, fruits and vegetables such 
as artichoke, asparagus, banana, barley, chicory, garlic, leeks, oats, onion, rye, soybeans, 
tomatoes and wheat are sources of non-digestible oligosaccharides, especially inulin (Davis 
& Milner, 2009; Femia et al., 2002; Losada & Olleros, 2002; Manning & Gibson, 2004; 
Mussatto & Mancilha, 2007; Sangeetha et al., 2005). They are also present in burdock, 
Chinese chives, garlic, graminae (fodder grass), pine, even bacteria and yeasts (Bengmark et 
al., 2001; Ziemer & Gibson, 1998). Honey and bamboo shoots are natural sources of 
isomaltulose (Lina et al., 2002). Raffinose and stachyose can be found in soyabeans and other 
leguminous seeds and pulses (Voragen, 1998). Milk is a good source of glycoproteins and 
oligosaccharides (lacto-N-tetraose and lacto-N-neotetraose), including those believed to be 
prebiotic (Alander et al., 2001; Newburg, 2000; Petschow & Talbott, 1991). Human milk 
contains more galactooligosaccharides than cow’s milk. Oligosaccharides can be found in 
levels as high as (12g/l), making them the third bulkiest constituent of human milk 
(Newburg et al., 2004). Taking foods containing prebiotic oligosaccharides is not enough for 
modulation of gut flora as they are present in only small concentrations in these foods. 
Instead, prebiotics are extracted from these foods and transferred into more commonly 
ingested foodstuffs like biscuits and other carbohydrate based materials (Taylor et al., 1999).  
These natural compounds can also be produced commercially through enzyme hydrolysis 
and extraction processes (Losada & Olleros, 2002; Mussatto & Mancilha, 2007; Sako et al., 
1999). The enzymes employed include β-D-fructofuranosidase or fructosyltransferase, which 
joins the fructose molecules by means of transfructosylation mechanisms (Losada & Olleros, 
2002). These mechanisms are employed for production of oligosaccharides with the 
exception of raffinose, soybean oligosaccharides and lactulose (Mussatto & Mancilha, 2007; 
Sako et al., 1999). Raffinose and soybean oligosaccharides are extracted directly from plant 
materials using solvents such as water, aqueous methanol or ethanol (Johansen et al., 1996; 
Mussatto & Mancilha, 2007). Lactulose is produced by enzymatic action of β-galactosidases 
(E.C 3.2.1.23) on lactose. The glucose moiety is converted to a fructose residue by alkali 
isomerization and the process results in a lactulose disaccharide (Villamiel et al., 2002). 
Inulin can also be extracted from chicory (Cichorium intybus) and then partially hydrolyzed 
to short-chain fructans (oligofructose) using inulase (E.C 3.2.1.7) or to long chain fructans by 
applying an industrial separation technique (Roberfroid, 2000). Additionally, inulin type 
fructans can be manufactured through transfer of fructosyl residue to and between sucrose 
molecules using fungal fructosyl transferases (E.C 2.4.1.9) (Cummings & Roberfroid, 1997). 
FOSs are manufactured from sucrose using the trans-fructosylation activity of β-
fructofuranosidase (E.C 3.2.1.26). Alternatively, FOS can are produced by controlled 
enzymatic hydrolysis of inulin (Crittenden & Playne, 1996; Frost & Sullivan, 2000). Lactose 
is also used in the industrial production of GOS through the transgalactosylation activity of 
β-galactosidases (Sako et al., 1999). The production of FOS and GOS requires high 
concentrations of the starting material for efficient transglycosylation (Park & Almeida, 
1991). GOS are synthesized from lactose syrup using the enzyme β-galactosidase (Frost & 
Sullivan, 2000; Gibson, 2004). They are neither hydrolyzed nor absorbed in the human 
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intestine and act as a substrate for bifidobacteria (Frost & Sullivan, 2000). Soy 
oligosaccharides are extracted directly from soybean whey. Their bifidogenecity has been 
confirmed in humans (Frost & Sullivan, 2000). 
3.1 Beneficial effects of prebiotics 
In the last decade there have been numerous investigations on the health-promoting effects 
of prebiotics. Bifidogenic oligosaccharides increase the level of nutrient supplementation 
and enhance nutrient solubility (Farmer, 2002). Some of these effects include better mineral 
absorption, alleviation of constipation and irritable bowel syndrome, protection against 
colon cancer, enhancement of the immune system, anticarcinogenic effects and lowering of 
cholesterol (Davis & Milner, 2009; Manning & Gibson, 2004; Tuohy et al., 2003; Venter, 
2007). Supplementation of diet with oligofructose and inulin-type oligosaccharides 
significantly lowers serum triglycerols and phospholipids. This hypotriacylyglycerolaemic 
effect could be caused by a decrease in the concentration of plasma very low-density 
lipoproteins (VLDL) (Delzenne et al., 1993; Fordaliso et al., 1995). Prebiotics acidifies colonic 
contents by increasing the concentration of short-chain carboxylic acids. They also aid in 
colonic absorption of minerals, particularly Mg2+ and Ca2+. Mineral absorption is promoted 
through establishment of an osmotic effect whereby entry of water into the colon increases 
dissolution of minerals (Roberfroid, 2000).  
Ingestion of prebiotics is also associated with relief of constipation due to faecal bulking and 
possible effects on intestinal motility, aiming at daily defecation. They suppress diarrhoea 
when it is associated with intestinal infections. They also reduce the risk of osteoporosis 
when improved bioavailability of calcium due to use of inulin-type fructans is followed by 
significant increase in bone density and bone mineral content. Prebiotics reduce the risk of 
obesity and possibly type-2 diabetes (van Loo et al., 1999). 
Most of the studies on prebiotic effects on bone development have been done on animal 
models, particularly rats (Scholz-Ahrens, 2007). In vivo studies carried out on humans 
showed that inulin and oligofructose increase the absorption of calcium but not iron, zinc or 
magnesium (Coudray et al., 1997). More research needs to be done to substantiate these 
claims, including that of bowel cancer prevention (Ziemer & Gibson, 1996). Studies that 
have been carried out on animal models so far have shown promise, though human studies 
are required (Reddy et al., 1997; Rowland et al., 1998). It is vital for studies conducted in 
vitro on prebiotic effects to be carried out in vivo in well-designed and reproducible 
experiments. 
Prebiotics, unlike probiotics, are not living organisms, and therefore they do not have 
survival problems both in the products and the gut (Frost & Sullivan, 2000). Prebiotics have 
an advantage over probiotics in that they are not affected by factors such as oxygen and heat 
in industrial applications. This attribute led to increased interest in their health issues (Kolita 
et al., 2002). Some commercially available prebiotic supplements are water-soluble. 
Solubility in water allows their possible incorporation in any type of food and also renders 
them undetectable once dissolved (Douglas & Sanders, 2008).  
However their excess levels can cause symptoms such as flatulence, bloating and diarrhoea. 
This may be caused by a change in osmotic potential or due to excessive fermentation. 
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Undesirable effects occur when very high doses are ingested. This is advantageous as it 
allows a relatively broad “therapeutic window”, i.e. the dose above the minimal effective 
level (Holzapfel & Schillinger, 2002). However, FOSs are slightly laxative and produce 
flatulence when taken in high doses (Losada & Olleros, 2002). 
4. Synbiotics 
Synbiotics are preparations containing a mixture of a probiotic and a prebiotic, or a 
combination of probiotics and prebiotics (Davis & Milner, 2009; Holzapfel & Schillinger, 
2002; Touhy et al., 2003). These preparations aim to improve the viability of the proven 
probiotic in vivo as well as stimulate the indigenous gut microflora. They provide both the 
beneficial microbial culture and a specific substrate that can be readily available for 
fermentation by this culture (Gallaher & Khil, 1999). The presence of the readily fermentable 
substrate could enhance the survival of the probiotic. The prebiotic ingredient could also 
offer protection of probiotic against gastric acidity and proteolysis, probably through steric 
hindrance and coating of the probiotic.  
Synbiotic supplements available include combinations of bifidobacteria and FOS, 
Lactobacillus GG and inulin and a combination of bifidobacteria lactobacilli with either FOS 
or inulin. Fermented milks contain both live beneficial bacteria and fermentation products 
that may positively stimulate the intestinal microflora also fall within this category. 
Crittenden et al. (2006) encapsulated a B. infantis-FOS synbiotic within a film-forming 
protein-carbohydrate-oil emulsion to improve its survival and viability during non-
refrigerated storage and GIT transit. Gallaher et al. (1996) observed a comparable synbiotic 
effect with oligofructose and bifidobacteria. Lactobacilli/lacitol, and bifidobacteria/GOS 
combinations have also been tried as synbiotics in addition to bifidobacteria/FOS 
(Mountzouris et al., 2002). A well-known benefit of synbiotics is that they increase the 
persistence of the probiotic in the GIT (Tuohy et al., 2003). The use of synbiotics has not been 
extensively explored, though studies indicated positive results with regard to maintenance 
of gut microflora (Shimizu et al., 2009). Their possible use for prevention of allergic diseases 
is just an example of the studies that still needs to be covered (Johannsen & Prescott, 2009).  
5. Conclusion 
Probiotics are beneficial microorganism with a host of benefits for the consumer though 
some of these benefits still have to be confirmed using clinical trials. There is however still a 
problem of maintenance of viability of these cultures both in storage and in the 
gastrointestinal tract. The search for methods that can protect and retain viability of 
probiotic cultures is still on going. There are also concerns about the negative effects of 
probiotics on sensitive consumers but there is insufficient evidence to support the raised 
concerns. Prebiotics and synbiotics are alternative mechanisms for increasing the levels of 
beneficial microorganisms in the gut. 
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